About MSD Pharmaceuticals Private Limited
Data last updated:
MSD Pharmaceuticals Private Limited is a private limited company based in New Delhi, Delhi, India, a subsidiary of Merck Sharp & Dohme B.V.. It operates in the pharmaceutical retail and distribution segment of the pharmaceuticals sector. It was incorporated on 03 December 2004 and has been in existence for over 22 years.
The company is registered with the Registrar of Companies (ROC), Delhi, under CIN U24230DL2004PTC164459. Its GSTIN is 07AAECM1106C1Z7 (Delhi). The company holds 18 GST registrations, of which 11 are active.
The company has an authorised share capital of ₹15 Cr and a paid-up capital of ₹13.2 Cr. It is led by directors Rehan Khan Abbas (Managing Director) and Chand Berry (Whole-Time Director).
Its last annual general meeting (AGM) was held on 29 August 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at 1544 Level 15 Eros Corporate Towers Nehru Place, New Delhi, Delhi, India – 110019.
As per the financials filed for FY 2025, the company reported a revenue of ₹2,748.9 Cr, a growth of 35% compared to the previous year. For the same year it recorded a net profit of ₹352.63 Cr (net margin 12.8%) and EBITDA of ₹551.03 Cr (EBITDA margin 20%). Revenue has grown at a compounded annual rate (CAGR) of 21% over three years and 15% over five years.
The company has about 783 employees on its provident fund (EPFO) records.
The company is associated with 1 brand: Merck Sharp & Dohme. Court records list 18 cases involving the company, including 6 filed by the company and 12 filed against it; 4 cases are pending. The company has 1 deal on record (1 secondary share transfer); the latest was in June 2007. The company has 11 MSME Form 1 returns on record between 2019 and 2023, listing 391 overdue payments to 52 micro and small suppliers.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website msdindia.in.
Company details
CIN history
MSD Pharmaceuticals has one previous CIN (Corporate Identification Number): U24230MH2004PTC149814. The current CIN is U24230DL2004PTC164459, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| U24230DL2004PTC164459 | Current |
| U24230MH2004PTC149814 | Previous |
Contact details
MSD Pharmaceuticals Private Limited's registered office is in New Delhi, Delhi. Its website is msdindia.in. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Social Media
- Registered Address1544 Level 15 Eros Corporate Towers Nehru Place, New Delhi, Delhi, India – 110019
- IndustryPharma, Pharmaceutical Retailers & Distributors
To see the full contact details of MSD Pharmaceuticals Private Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Brands
MSD Pharmaceuticals operates one associated brand: Merck Sharp & Dohme. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Therapies for HIV, cancer, diabetes, and infectious diseases are developed. | msd.com |
Business activity
The main business activity of MSD Pharmaceuticals is wholesale and retail trade; repair of motor vehicles and motorcycles. In detail, this covers wholesale trade, except of motor vehicles and motorcycles.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| G | Wholesale and retail trade; repair of motor vehicles and motorcycles | 46 | Wholesale trade, except of motor vehicles and motorcycles |
To see the full business activity and turnover split of MSD Pharmaceuticals Private Limited, buy the company report.
Financials of MSD Pharmaceuticals Private Limited
FY 2025 filings availableMSD Pharmaceuticals Private Limited reported revenue of ₹2,748.9 Cr (up 35% YoY) for FY 2025.
Compounded Annual Growth Rate (CAGR)
Revenue has grown at a compounded annual rate (CAGR) of 15% over five years, including 35% growth in the latest year. EBITDA rose 6% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | ₹2,748.9 Cr | ||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | ₹551.03 Cr | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | ₹352.63 Cr | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 20% | ||||
| Net Profit Margin | 12.8% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of MSD Pharmaceuticals Private Limited, buy the company report.
Board of directors of MSD Pharmaceuticals Private Limited
MSD Pharmaceuticals has 2 current directors and 17 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Chand Berry | Whole-Time Director | 30 Sep 2021 | 5 Years 1 Months | Current |
| Rehan Khan Abbas Also directs: Metropolis Healthcare Limited | Managing Director | 07 May 2021 | 5 Years 6 Months | Current |
Auditor
MSD Pharmaceuticals Private Limited is audited by Lovelock & LewesChartered Accountants LLP for the financial year 2025.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| Lovelock & LewesChartered Accountants LLP | FY 2025 | 301056E/E300265 |
Shareholding
The shareholding of MSD Pharmaceuticals Private Limited is on record for 5 financial years, the latest being FY 2025, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Promoters | |||||
| Domestic institutional investors (DII) | |||||
| Foreign institutional investors (FII) | |||||
| Public | |||||
| Others |
To see the full shareholding pattern of MSD Pharmaceuticals Private Limited, buy the company report.
Deals & funding
MSD Pharmaceuticals Private Limited has 1 deal on record (1 secondary share transfer); the latest was in June 2007.
Deals on record (1 of 1)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Jun 2007 | Secondary share transfer | Undisclosed | Buyer: MSD Finance B V, Msd Human Health Holding B.v. (Msd Hhh B.v.) Seller: 2 individuals |
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
MSD Pharmaceuticals Private Limited has 18 court cases on record: 6 filed by MSD Pharmaceuticals, 12 filed against it. 4 cases are pending and 14 are disposed.
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| High courts | 10 | 6 | 3 |
| District courts | 4 | 2 | 0 |
| Supreme Court | 4 | 4 | 1 |
Cases on record (5 of 18)
| Court | Type of case | Party | Status |
|---|---|---|---|
| District court, Gangtok, Sikkim | Court case (Us 148 (a) (caveat)) | Filed against the company by Glenmark Generics Ltd, | Disposed |
| High Court of Delhi | Writ petition | Filed by the company against The Principal Commissioner of Income Tax- 4, New Delhi & Ors. | Pending |
| High Court | Court case (WPL) | Filed against the company by an individual | Pending |
| High Court, KARNATAKA | Writ petition | Filed by the company against individuals | Pending |
| Supreme Court | Court case (Special Leave Petition (Civil)) | Filed against the company by The PR. Commissioner of Income Tax 6 | Pending |
To see the full case history of MSD Pharmaceuticals Private Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
MSME payment delays
MSD Pharmaceuticals Private Limited has 11 MSME Form 1 returns on record between 2019 and 2023, listing 391 overdue payments to 52 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.
Suppliers with reported dues (5 of 52)
| Supplier | Amount due | Due since | Reported on |
|---|---|---|---|
| an individual supplier | |||
| FCC Logistics Private Limited | |||
| an individual supplier | |||
| an individual supplier | |||
| Ambetronics Engineers Private Limited |
To see the full MSME payment records of MSD Pharmaceuticals Private Limited, buy the company report.
Individuals and sole proprietors among the suppliers are not named.
Employees & EPFO
MSD Pharmaceuticals Private Limited has a workforce of 783 employees on its EPFO records as of May 2026, across 2 active EPFO establishments.
Headcount by financial year
| Financial year | Employees (EPFO) |
|---|---|
| FY 2026-27 | 783 |
| FY 2025-26 | |
| FY 2024-25 | |
| FY 2023-24 | |
| FY 2022-23 | |
| FY 2021-22 | |
| FY 2020-21 | |
| FY 2019-20 | |
| FY 2018-19 | |
| FY 2017-18 | |
| FY 2016-17 | |
| FY 2013-14 |
To see the full employee and EPFO history of MSD Pharmaceuticals Private Limited, buy the company report.
GST
MSD Pharmaceuticals has 18 GST registrations: 11 active and 7 cancelled or inactive. The first 4 active GSTINs are listed below.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 07AAECM1106C1Z7 | Delhi | Active | 01 Jul 2017 |
| 06AAECM1106C1Z9 | Haryana | Active | 01 Jul 2017 |
| 08AAECM1106C1Z5 | Rajasthan | Active | 01 Jul 2017 |
| 19AAECM1106C1Z2 | West Bengal | Active | 01 Jul 2017 |
To see the full GST registrations and return filing status of MSD Pharmaceuticals Private Limited, buy the company report.
Recent activity
MSD Pharmaceuticals Private Limited has 34 board changes on record since 2004: 18 appointments and 16 cessations. The latest: Yashodhara Dilip Ghorpade ceased to be Whole-Time Director on 10 Oct 2025.
25 earlier events are in the company report.
News
Frequently asked questions
MSD Pharmaceuticals is an active private limited company based in New Delhi, Delhi, India. The company works in pharmaceutical retailers and distributors, within the pharma industry. It was incorporated on 03 December 2004 (22+ years old) and is registered under CIN U24230DL2004PTC164459.
MSD Pharmaceuticals has 2 current directors:
- Rehan Khan Abbas - Managing Director
- Chand Berry - Whole-Time Director
The latest financial statements of MSD Pharmaceuticals on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 29 August 2025. Year-wise statements from 2015 are in the company report.
The GSTIN of MSD Pharmaceuticals is 07AAECM1106C1Z7, registered in Delhi. The company has 18 GST registrations in all, of which 11 are active and 7 are cancelled or inactive. Other active GSTINs include 06AAECM1106C1Z9 (Haryana), 08AAECM1106C1Z5 (Rajasthan), 19AAECM1106C1Z2 (West Bengal).
The CIN (Corporate Identification Number) of MSD Pharmaceuticals is U24230DL2004PTC164459. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
MSD Pharmaceuticals has 18 court cases on record: 6 filed by the company and 12 filed against it. 4 are pending. Most are in the high courts.
MSD Pharmaceuticals was incorporated on 03 December 2004, making it 22+ years old. It is registered with the Registrar of Companies, Delhi.
MSD Pharmaceuticals has 1 deal on record (1 secondary share transfer); the latest was in June 2007.
Yashodhara Dilip Ghorpade ceased to be Whole-Time Director on 10 Oct 2025. Yashodhara Dilip Ghorpade was appointed as Whole-Time Director on 06 Sep 2023. Muralidhar Venkata Karanam ceased to be Whole-Time Director on 24 Aug 2023. MSD Pharmaceuticals has 34 board changes on record in total.
MSD Pharmaceuticals has 11 MSME Form 1 returns on record between 2019 and 2023, listing 391 overdue payments to 52 micro and small suppliers. The latest return was filed on 05 Nov 2023.
MSD Pharmaceuticals can be reached through the website msdindia.in. Its registered office is in New Delhi, Delhi, India.
Sample company reports
The same report you get when you buy one: financials, directors, ownership, deals, charges, legal cases, brands and filings, with the Excel workbook alongside.
